Lung Cancer Dispatch
4.6K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

No Survival Benefit of Video-Assisted Thoracoscopic Partial Pleurectomy vs Talc Pleurodesis in Malignant Pleural Mesothelioma

"In light of nonrandomized studies suggesting benefit of video-assisted thoracoscopic partial pleurectomy (VAT-PP) in symptom control and survival, Rintoul et al performed a randomized trial (MesoVATS) of VAT-PP vs talc pleurodesis in malignant pleural mesothelioma. As reported in The Lancet, this UK study showed no survival improvement, more frequent complications, and longer hospital stay with VAT-PP."


Editor's note: A study with volunteer mesothelioma patients aimed to compare two treatments: video-assisted thoracoscopic partial pleurectomy (VAT-PP) and talc pleurodesis. All patients in the trial had malignant pleural mesothelioma with pleural effusion. The researchers wished to figure out which treatment was better in terms of symptom control and survival. They found that, between the two treatments, there was no significant difference in the number of patients still alive one year later. Also, patients treated with VAT-PP had more frequent complications and longer hospital stays.

Cancer Commons's insight:

The ASCO Post  |  Jul 7, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Aduro Announces ASCO Presentation of Promising Results from Phase 1b Clinical trial of its Novel Immunotherapy for the Treatment of Mesothelioma

Aduro Announces ASCO Presentation of Promising Results from Phase 1b Clinical trial of its Novel Immunotherapy for the Treatment of Mesothelioma | Lung Cancer Dispatch | Scoop.it

"Aduro BioTech, Inc., a clinical stage biotechnology company, today announced the presentation of safety and efficacy data from a Phase 1b clinical trial of its novel immunotherapy CRS-207 in combination with standard chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). Of the 16 evaluable patients, 69% (11/16) had confirmed durable partial responses (PR) with 25% (4/16) experiencing stable disease (SD) after CRS-207 and chemotherapy. The results were presented by Raffit Hassan, M.D., co-chief of the Thoracic and GI Oncology Branch at the National Cancer Institute, in a poster presentation at the 2014 American Society of Clinical Oncology Meeting (ASCO) held in Chicago."


Editor's note: Scientists have developed a new drug called CRS-207 for treating mesothelioma. CRS-207 is an immunotherapy, meaning that it boosts a patient's own immune system to fight cancer. A clinical trial testing CRS-207 in volunteer patients found promising results for the drug.

Cancer Commons's insight:

StreetInsider  |  Jun 2, 2014

more...
Krishan Maggon 's curator insight, June 5, 2014 2:39 AM

CRS-207, based on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenesimmunotherapy platform, has been engineered to induce a potent innate immune response as well as an adaptive immune response targeting mesothelin, an antigen over-expressed in MPM tumors.


CRS-207 plus GVAX in a Phase II advanced pancreatic cancer trial (ECLIPSE) in 93 evaluable patients extended overall survival to 6.1 months from the GVAX arm alone.

Scooped by Cancer Commons
Scoop.it!

Analysis Finds No Survival Advantage from Mesothelioma Surgery, According to Surviving Mesothelioma

"A new article in the Journal of Thoracic Surgery says a certain subset of mesothelioma patients is unlikely to see much of a survival benefit from surgery. As Surviving Mesothelioma reports, researchers from six different Italian institutions analyzed survival data on 1,365 consecutive mesothelioma patients treated between 1982 and 2012."

Cancer Commons's insight:

PRWeb  |  Feb 25, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

New Cancer Drug ADI-PEG 20 May 'Starve Out' Mesothelioma

New Cancer Drug ADI-PEG 20 May 'Starve Out' Mesothelioma | Lung Cancer Dispatch | Scoop.it

Early promising results are emerging for ADI-PEG 20, a new cancer drug that breaks down arginine. Arginine is an amino acid—a building block for proteins—that is necessary for cell function. Normal cells can produce their own arginine, but many tumor cells cannot. By depriving the body of arginine, ADI-PEG selectively disrupts cancer cells. In a phase II clinical trial, ADI-PEG prolonged the time without cancer progression in patients with malignant pleural mesothelioma, a type of lung cancer. Almost half of the patients had a partial response to the drug, defined as their tumors shrinking at least 30%.

Cancer Commons's insight:

Yahoo! Finance | Oct. 28, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Two New Trials of Mesothelioma Treatments Begin in the UK

Mesothelioma is a form of lung cancer strongly associated with exposure to asbestos. Even though asbestos has been banned or heavily regulated in most developed nations, due to delayed onset, the number of mesothelioma cases is predicted to climb until around 2020. In the UK, which has the highest mesothelioma incidence worldwide, two new clinical trials are aiming to find treatments for the disease. The Meso2 trial will investigate ganetespib, while the COMMAND trial will examine defactinib. Defactinib specifically targets cancer stem cells, which often survive cancer treatment and cause cancer recurrence. The drug may therefore help prevent relapse after first-line therapy.

Cancer Commons's insight:

ScienceDaily | Sep 23, 2013

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Biomarkers Accurately Distinguish Mesothelioma from Non-Cancerous Tissue

Biomarkers Accurately Distinguish Mesothelioma from Non-Cancerous Tissue | Lung Cancer Dispatch | Scoop.it

"Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations (RMPs). This is a frequent differential diagnostic problem in pleural biopsy samples taken from patients with clinical suspicion of MPM. The ability to make more accurate diagnoses earlier may facilitate improved patient outcomes. This new study appears in the Journal of Molecular Diagnostics."


Editor's note: Diagnosis of cancer is not always straightforward. New techniques allow doctors to use the molecular/genetic characteristics of a tumor to more quickly and accurately diagnose cancer. In the research described here, scientists identified new molecular characteristics ("biomarkers") that could be used to help identify mesothelioma tumors.

Cancer Commons's insight:

Medical Xpress  |  Jun 6, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Tracer Could Indicate Radiation Benefit to Patient

Tracer Could Indicate Radiation Benefit to Patient | Lung Cancer Dispatch | Scoop.it

"A world-first radiotherapy treatment trial by University of WA researchers could have a major impact on the quality of life for mesothelioma patients.


"Funded by an almost $100,000 Cancer Council WA grant, the research team is exploring why some patients respond to radiotherapy treatment while others don't, as well as developing tests to predict whether patients will respond to avoid people being treated unnecessarily."

Cancer Commons's insight:

Medical Xpress  |  Jun 3, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Radiation Before Surgery May Increase Survival in Mesothelioma Patients

Radiation Before Surgery May Increase Survival in Mesothelioma Patients | Lung Cancer Dispatch | Scoop.it

A study in 25 patients with mesothelioma, a type of lung cancer associated with exposure to asbestos, suggests that radiation treatment before surgery can significantly increase survival. Patients were treated using a new approach dubbed SMART (Surgery for Mesothelioma After Radiation Therapy). They received an accelerated, 5-day course of intensity-modulated radiation therapy (IMRT), which conforms the radiation dose around the tumors while sparing nearby healthy tissues. They then underwent surgery to remove the affected lung. Seventy-two percent of patients survived 3 years or more after treatment; 3-year survival rates without SMART rank at 32%. People with known exposure to asbestos who experience shortness of breath, weight loss, and fatigue for more than 3 weeks should be evaluated by a doctor to ensure speedy access to treatment.

Cancer Commons's insight:

ScienceDaily  |  Jan 20, 2014

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Previously Neglected Lymph Nodes Are Significant in Mesothelioma

To assess cancer stage, that is, how far advanced a cancer is, doctors routinely examine lymph nodes. However, a subset of lymph nodes located between the ribs near the spine, the so-called posterior intercostal lymph nodes, are not usually assessed in cancer staging. In a retrospective study of patients who had undergone surgery for mesothelioma (a type of lung cancer associated with asbestos exposure), researchers found that the cancer had spread to the posterior intercostal lymph nodes in over half of these patients. Patients who had no evidence of cancer in the posterior intercostal lymph nodes lived nearly 2.5 years longer, on average, than those who had. The posterior intercostal lymph nodes appear to be highly significant and should be biopsied routinely in mesothelioma patients.

Cancer Commons's insight:

Penn Medicine | Oct 28, 2013

more...
No comment yet.
Suggested by Cancer Commons
Scoop.it!

Advocacy Group: Lung Cancer Patients Who Have Been Exposed to Asbestos May be Eligible for Compensation

Advocacy Group: Lung Cancer Patients Who Have Been Exposed to Asbestos May be Eligible for Compensation | Lung Cancer Dispatch | Scoop.it

The Lung Cancer Asbestos Victims Center has launched a national campaign emphasizing that patients diagnosed with any type of lung cancer, not just mesothelioma, may be eligible for significant financial compensation if they have been exposed to asbestos in the workplace, even if the exposure occurred decades ago. The advocacy group lists the types of workplaces with the highest risk of asbestos exposure on their website. Patients or their family members can contact the organization at 866-714-6466 to get more information and to be directed to an experienced law firm.

Cancer Commons's insight:

PRWeb | Jan 31, 2013

more...
No comment yet.